Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Current Deferred Revenue (2018 - 2024)

Dna X filings provide 7 years of Current Deferred Revenue readings, the most recent being $12000.0 for Q2 2024.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $12000.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $12000.0, a N/A change, with the full-year FY2023 number at $12000.0, down 61.29% from a year prior.
  • Current Deferred Revenue hit $12000.0 in Q2 2024 for Dna X, roughly flat from $12000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $872000.0 in Q2 2021 to a low of $3000.0 in Q1 2023.
  • Median Current Deferred Revenue over the past 5 years was $31000.0 (2022), compared with a mean of $166933.3.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 98.28% in 2020 and later soared 300.0% in 2024.
  • Dna X's Current Deferred Revenue stood at $5000.0 in 2020, then soared by 120.0% to $11000.0 in 2021, then soared by 181.82% to $31000.0 in 2022, then tumbled by 61.29% to $12000.0 in 2023, then changed by 0.0% to $12000.0 in 2024.
  • The last three reported values for Current Deferred Revenue were $12000.0 (Q2 2024), $12000.0 (Q1 2024), and $12000.0 (Q4 2023) per Business Quant data.